|
EP2023940B1
(en)
|
2006-05-05 |
2011-06-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
|
ES2377327T5
(es)
*
|
2006-10-18 |
2020-04-28 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
US8580756B2
(en)
*
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
US8318496B2
(en)
*
|
2007-10-04 |
2012-11-27 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improving cellular uptake of oligomeric compounds
|
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
US8334372B2
(en)
|
2008-10-15 |
2012-12-18 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
WO2010064146A2
(en)
|
2008-12-02 |
2010-06-10 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
CA2767253A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc. |
Novel nucleic acid prodrugs and methods of use thereof
|
|
AU2011213562B2
(en)
|
2010-02-08 |
2016-07-07 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
EP2534262B1
(en)
|
2010-02-08 |
2016-12-14 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
DK3031920T3
(da)
|
2010-07-19 |
2019-10-14 |
Ionis Pharmaceuticals Inc |
Modulation af dystrofi myotonica-protein kinase (dmpk) ekspression
|
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
JP6336755B2
(ja)
|
2010-11-12 |
2018-06-06 |
ザ ジェネラル ホスピタル コーポレイション |
ポリコームに関連する非コードｒｎａ
|
|
JP6126009B2
(ja)
|
2010-11-17 |
2017-05-10 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
α−シヌクレイン発現の調節
|
|
EP3067421B1
(en)
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
WO2012161806A1
(en)
*
|
2011-02-25 |
2012-11-29 |
Isis Pharmaceuticals, Inc. |
Modulation of stat3 expression
|
|
CR20190207A
(es)
|
2011-04-21 |
2019-06-26 |
Ionis Pharmaceuticals Inc |
MODULACIÓN DE LA EXPRESIÓN DEL VIRUS DE LA HEPATITIS B (VHB) (Divisional 2013-0551)
|
|
US9353371B2
(en)
|
2011-05-02 |
2016-05-31 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
|
CN103796657B
(zh)
|
2011-07-19 |
2017-07-11 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
|
WO2013022966A1
(en)
*
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Linkage modified gapped oligomeric compounds and uses thereof
|
|
EP3533873A1
(en)
|
2011-09-14 |
2019-09-04 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
US9243291B1
(en)
*
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
|
EP2839008A4
(en)
*
|
2012-03-12 |
2015-12-02 |
Roche Innovation Ct Copenhagen As |
COMPOSITIONS AND METHODS FOR MODULATING ATXN3 EXPRESSION
|
|
US9914922B2
(en)
|
2012-04-20 |
2018-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
|
DK2850186T3
(en)
|
2012-05-16 |
2019-04-08 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
CA2873797A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating utrn expression
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
CN104583400A
(zh)
*
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节pten表达的组合物和方法
|
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
|
KR20190084354A
(ko)
|
2012-05-24 |
2019-07-16 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 (a) 발현을 조절하는 방법들 및 조성물들
|
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
WO2014010250A1
(en)
|
2012-07-13 |
2014-01-16 |
Chiralgen, Ltd. |
Asymmetric auxiliary group
|
|
CA2879066C
(en)
|
2012-07-13 |
2019-08-13 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
キラル制御
|
|
JP2015529469A
(ja)
|
2012-09-14 |
2015-10-08 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
EP2906255B1
(en)
*
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
ES2657608T3
(es)
*
|
2012-12-05 |
2018-03-06 |
Alnylam Pharmaceuticals, Inc. |
Composiciones de arni de pcsk9 y métodos de uso de las mismas
|
|
AU2014222150A1
(en)
|
2013-03-01 |
2015-09-10 |
National University Corporation Tokyo Medical And Dental University |
Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
|
|
ME03043B
(me)
|
2013-03-14 |
2018-10-20 |
Alnylam Pharmaceuticals Inc |
Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
|
|
RU2670614C9
(ru)
|
2013-05-01 |
2018-11-23 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы модулирования экспрессии hbv и ttr
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
US20170268000A1
(en)
|
2013-12-02 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
|
KR20230152178A
(ko)
|
2014-01-16 |
2023-11-02 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
|
ES2890677T3
(es)
|
2014-03-19 |
2022-01-21 |
Ionis Pharmaceuticals Inc |
Composiciones para modular la expresión de ataxina 2
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
NZ724100A
(en)
|
2014-04-01 |
2022-12-23 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
CA2943894A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating complement factor b expression
|
|
US10472634B2
(en)
|
2014-06-04 |
2019-11-12 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting apolipoprotein E receptor 2
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
US10301624B2
(en)
|
2014-06-25 |
2019-05-28 |
The General Hospital Corporation |
Targeting human satellite II (HSATII)
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
AU2015318782A1
(en)
|
2014-09-18 |
2017-04-06 |
The University Of British Columbia |
Allele-specific therapy for Huntington Disease haplotypes
|
|
AU2015327836B2
(en)
|
2014-10-03 |
2021-07-01 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
|
US10858650B2
(en)
|
2014-10-30 |
2020-12-08 |
The General Hospital Corporation |
Methods for modulating ATRX-dependent gene repression
|
|
US20180112217A1
(en)
*
|
2014-11-19 |
2018-04-26 |
Roche Innovation Center Copenhagen A/S |
Stereospecific Phosphorothioate LNA
|
|
CN107208092B
(zh)
|
2014-12-16 |
2021-09-10 |
罗氏创新中心哥本哈根有限公司 |
手性毒性筛选方法
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
US11077132B2
(en)
|
2015-02-04 |
2021-08-03 |
F. Hoffmann-La Roche Ag |
Tau antisense oligomers and uses thereof
|
|
CN115181778A
(zh)
|
2015-02-04 |
2022-10-14 |
百时美施贵宝公司 |
选择治疗性分子的方法
|
|
CA2976576A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating rna
|
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
MA43072A
(fr)
*
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
|
EP3359685A1
(en)
|
2015-10-09 |
2018-08-15 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
EP3389670A4
(en)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
METHODS OF TREATING BREAST CANCER
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
ES2882500T3
(es)
|
2015-12-14 |
2021-12-02 |
Cold Spring Harbor Laboratory |
Oligómeros antisentido para el tratamiento del síndrome de Dravet
|
|
US20190002887A1
(en)
|
2015-12-31 |
2019-01-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
WO2017120365A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
|
JP6853537B2
(ja)
|
2016-02-17 |
2021-03-31 |
国立大学法人東京工業大学 |
人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
CN109757108A
(zh)
*
|
2016-07-05 |
2019-05-14 |
比奥马林技术公司 |
具有治疗遗传疾病的改善特征的包含双环支架部分的前体mRNA剪接转换或调节寡核苷酸
|
|
WO2018055577A1
(en)
*
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
|
CA3037663A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified-rna oligonucleotide compositions and uses thereof
|
|
WO2018062510A1
(ja)
|
2016-09-29 |
2018-04-05 |
国立大学法人東京医科歯科大学 |
オーバーハングを有する二本鎖核酸複合体
|
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
JP2019535839A
(ja)
|
2016-11-29 |
2019-12-12 |
ピュアテック ヘルス エルエルシー |
治療剤の送達のためのエクソソーム
|
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
|
TWI830693B
(zh)
|
2017-02-06 |
2024-02-01 |
日商日產化學工業股份有限公司 |
單股寡核苷酸
|
|
JP7095893B2
(ja)
|
2017-02-21 |
2022-07-05 |
国立大学法人大阪大学 |
アンチセンスオリゴ核酸
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
WO2019004420A1
(ja)
|
2017-06-30 |
2019-01-03 |
国立大学法人東京医科歯科大学 |
ヘテロ二本鎖型ａｎｔｉｍｉＲ
|
|
JP7422068B2
(ja)
|
2017-08-08 |
2024-01-25 |
ウェーブ ライフ サイエンシーズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
CA3071033A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
RS65031B1
(sr)
|
2017-08-25 |
2024-02-29 |
Stoke Therapeutics Inc |
Antisens oligomeri za lečenje stanja i bolesti
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
EP3694995A1
(en)
|
2017-10-13 |
2020-08-19 |
Roche Innovation Center Copenhagen A/S |
Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
|
|
KR102585898B1
(ko)
|
2017-10-16 |
2023-10-10 |
에프. 호프만-라 로슈 아게 |
B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
JP2021505175A
(ja)
|
2017-12-11 |
2021-02-18 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｆｎｄｃ３ｂの発現を調節するためのオリゴヌクレオチド
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
CA3085211A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
EP3728591B1
(en)
|
2017-12-22 |
2025-07-23 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
AU2018386524A1
(en)
|
2017-12-22 |
2020-07-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
JP2021508327A
(ja)
|
2017-12-22 |
2021-03-04 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規のチオホスホラミダイト
|
|
CN111699258A
(zh)
|
2018-01-10 |
2020-09-22 |
哥本哈根罗氏创新中心 |
用于调控pias4表达的寡核苷酸
|
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
CN111902537A
(zh)
|
2018-01-15 |
2020-11-06 |
Ionis制药公司 |
Dnm2表达的调节剂
|
|
WO2019141656A1
(en)
|
2018-01-17 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｓｒｅｂｐ１を標的とするアンチセンスオリゴヌクレオチド
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
AU2019219194A1
(en)
|
2018-02-09 |
2020-08-06 |
Genentech, Inc. |
Oligonucleotides for modulating TMEM106B expression
|
|
CA3090901A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
EP3760209B1
(en)
|
2018-02-28 |
2023-11-22 |
National University Corporation Tokyo Medical and Dental University |
Ischemic-lesion-site-specific gene therapy
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
JP7394392B2
(ja)
|
2018-03-14 |
2023-12-08 |
国立大学法人 東京医科歯科大学 |
核酸複合体
|
|
JP7333079B2
(ja)
|
2018-03-19 |
2023-08-24 |
国立大学法人 東京医科歯科大学 |
毒性が軽減した核酸
|
|
CA3094303A1
(en)
|
2018-03-20 |
2019-09-26 |
Tokyo Institute Of Technology |
Antisense oligonucleotide reduced in toxicity
|
|
JP7262816B2
(ja)
|
2018-03-22 |
2023-04-24 |
国立大学法人 東京医科歯科大学 |
ヘテロ核酸のｂｂｂ通過脂質リガンド
|
|
EP3768694A4
(en)
|
2018-03-22 |
2021-12-29 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
EP3775204A4
(en)
|
2018-04-11 |
2021-12-29 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
JP2021523227A
(ja)
|
2018-05-04 |
2021-09-02 |
ストーク セラピューティクス，インク． |
コレステリルエステル蓄積症の処置のための方法及び組成物
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
CA3098136A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing fxi expression
|
|
JOP20200283A1
(ar)
|
2018-05-09 |
2020-11-08 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير الوراثي عن atxn3
|
|
WO2019233922A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
AU2019297391B2
(en)
|
2018-07-03 |
2023-01-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating Tau expression
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
MX2021000922A
(es)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de la atxn2.
|
|
US20210308170A1
(en)
|
2018-07-27 |
2021-10-07 |
Osaka University |
Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan
|
|
AU2019313443A1
(en)
|
2018-07-31 |
2020-11-26 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
EP4122943B1
(en)
|
2018-07-31 |
2024-05-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN112912499A
(zh)
|
2018-08-02 |
2021-06-04 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
EP3873920A1
(en)
|
2018-11-01 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting tia1
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
CA3119456A1
(en)
|
2018-11-15 |
2020-05-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of irf5 expression
|
|
US12281305B2
(en)
|
2018-11-21 |
2025-04-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
|
WO2020117706A1
(en)
*
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
EP3898975A2
(en)
|
2018-12-21 |
2021-10-27 |
Boehringer Ingelheim International GmbH |
Antisense oligonucleotides targeting card9
|
|
WO2020152303A1
(en)
|
2019-01-25 |
2020-07-30 |
F. Hoffmann-La Roche Ag |
Lipid vesicle for oral drug delivery
|
|
MX2021008918A
(es)
|
2019-01-31 |
2021-08-24 |
Ionis Pharmaceuticals Inc |
Moduladores de expresion yap1.
|
|
TW202045521A
(zh)
|
2019-02-20 |
2020-12-16 |
丹麥商羅氏創新中心哥本哈根有限公司 |
新穎亞磷醯胺化物
|
|
JP2022521510A
(ja)
|
2019-02-20 |
2022-04-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホノアセテートギャップマー型オリゴヌクレオチド
|
|
WO2020173845A1
(en)
|
2019-02-26 |
2020-09-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
|
SG11202108450SA
(en)
|
2019-02-27 |
2021-09-29 |
Ionis Pharmaceuticals Inc |
Modulators of malat1 expression
|
|
JP7530106B2
(ja)
|
2019-03-14 |
2024-08-07 |
レナセラピューティクス株式会社 |
Ｉｈｈ発現を調節するための核酸複合体
|
|
CN117431244A
(zh)
|
2019-03-29 |
2024-01-23 |
Ionis制药公司 |
用于调节ube3a-ats的化合物和方法
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
EP3980539A1
(en)
|
2019-06-06 |
2022-04-13 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting atxn3
|
|
HRP20251033T1
(hr)
|
2019-07-26 |
2025-10-24 |
Ionis Pharmaceuticals, Inc. |
Spojevi i postupci za moduliranje gfap
|
|
US20220370491A1
(en)
|
2019-09-18 |
2022-11-24 |
National University Corporation Tokyo Medical And Dental University |
Nucleic acid complex
|
|
EP4043565A4
(en)
|
2019-10-11 |
2024-01-24 |
National University Corporation Tokyo Medical and Dental University |
MODIFIED HETERONUCLEIC ACID
|
|
JP7640461B2
(ja)
|
2019-10-11 |
2025-03-05 |
住友化学株式会社 |
核酸オリゴマーの製造方法
|
|
CN114127292A
(zh)
*
|
2019-11-27 |
2022-03-01 |
国立大学法人东京工业大学 |
减轻反义核酸的毒性的方法
|
|
WO2021130266A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
MX2022007909A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
|
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
ES2981209T3
(es)
|
2020-01-29 |
2024-10-07 |
Sumitomo Chemical Co |
Proceso de preparación de oligómero de ácido nucleico
|
|
EP4098655A4
(en)
|
2020-01-29 |
2024-02-28 |
Sumitomo Chemical Company, Limited |
METHOD FOR PRODUCING NUCLEIC ACID OLIGOMERS
|
|
EP4098747A4
(en)
|
2020-01-31 |
2025-03-26 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
ATN1 ANTISENSE OLIGONUCLEOTIDE
|
|
AR121446A1
(es)
|
2020-02-28 |
2022-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
US20230159925A1
(en)
|
2020-03-04 |
2023-05-25 |
Nissan Chemical Corporation |
Antisense oligonucleotide of calm2
|
|
CN115335522A
(zh)
*
|
2020-03-05 |
2022-11-11 |
施能康公司 |
用于降低apoe表达的化合物和方法
|
|
JPWO2021187392A1
(enExample)
|
2020-03-16 |
2021-09-23 |
|
|
|
EP4130018A4
(en)
|
2020-03-27 |
2024-04-17 |
Sumitomo Chemical Company, Limited |
METHOD FOR PRODUCING A NUCLEIC ACID OLIGOMER
|
|
US20230151369A1
(en)
*
|
2020-04-17 |
2023-05-18 |
The University Of British Columbia |
Compositions and methods for inhibiting tdp-43 and fus aggregation
|
|
WO2021222768A2
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
|
AU2021270720A1
(en)
|
2020-05-11 |
2022-12-08 |
Stoke Therapeutics, Inc. |
OPA1 antisense oligomers for treatment of conditions and diseases
|
|
BR112022024206A2
(pt)
|
2020-06-29 |
2023-01-03 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular plp1
|
|
WO2022009959A1
(ja)
|
2020-07-09 |
2022-01-13 |
住友化学株式会社 |
核酸オリゴマーの製造方法
|
|
UY39344A
(es)
|
2020-07-28 |
2022-02-25 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de app
|
|
TW202221123A
(zh)
|
2020-08-07 |
2022-06-01 |
美商Ionis製藥公司 |
調節ｓｃｎ２ａ之化合物及方法
|
|
CN116209668A
(zh)
|
2020-09-24 |
2023-06-02 |
住友化学株式会社 |
核酸寡聚物的制造方法
|
|
MX2023005736A
(es)
|
2020-11-18 |
2023-05-25 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la expresion de angiotensinogeno.
|
|
US20230060373A1
(en)
|
2020-12-03 |
2023-03-02 |
Hoffmann-La Roche Inc. |
Antisense Oligonucleotides Targeting ATXN3
|
|
TW202237842A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ａｔｘｎ３之反義寡核苷酸
|
|
IL303800A
(en)
|
2020-12-18 |
2023-08-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating factor xii
|
|
EP4271816A4
(en)
|
2020-12-31 |
2025-04-02 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
|
|
WO2022162015A1
(en)
|
2021-01-26 |
2022-08-04 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
CA3219942A1
(en)
*
|
2021-05-10 |
2022-11-17 |
Q-State Biosciences, Inc. |
Compositions targeting sodium channel 1.6
|
|
US20240358845A1
(en)
|
2021-05-10 |
2024-10-31 |
Entrada Therapeutics, Inc. |
Compositions and methods for intracellular therapeutics
|
|
US20240240183A1
(en)
|
2021-05-25 |
2024-07-18 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid containing scpBNA or AmNA
|
|
JPWO2022255273A1
(enExample)
|
2021-05-31 |
2022-12-08 |
|
|
|
AU2022293556A1
(en)
|
2021-06-18 |
2024-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
|
EP4359006A1
(en)
|
2021-06-23 |
2024-05-01 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2023022229A1
(ja)
|
2021-08-19 |
2023-02-23 |
国立大学法人東京医科歯科大学 |
モルホリノ核酸を含む修飾ヘテロ核酸
|
|
EP4389893A4
(en)
|
2021-08-21 |
2025-09-10 |
Takeda Pharmaceuticals Co |
PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
US20250179486A1
(en)
|
2021-09-15 |
2025-06-05 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid including 2'-modified nucleoside
|
|
KR20240082343A
(ko)
|
2021-09-28 |
2024-06-10 |
스미또모 가가꾸 가부시끼가이샤 |
정제 디클로로아세트산의 제조 방법
|
|
JPWO2023080159A1
(enExample)
|
2021-11-02 |
2023-05-11 |
|
|
|
CN118318042A
(zh)
|
2021-11-03 |
2024-07-09 |
豪夫迈·罗氏有限公司 |
用于调节载脂蛋白e4表达的寡核苷酸
|
|
JP2024544532A
(ja)
|
2021-11-11 |
2024-12-03 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｈｂｖの処置のための医薬組合せ
|
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
EP4465994A1
(en)
|
2022-01-20 |
2024-11-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
CN119213005A
(zh)
|
2022-03-16 |
2024-12-27 |
艾姆皮瑞克公司 |
用于提高siRNA生物利用度的GALNAC组合物
|
|
WO2023182274A1
(ja)
|
2022-03-23 |
2023-09-28 |
住友化学株式会社 |
核酸オリゴマーの製造方法
|
|
WO2023192830A2
(en)
|
2022-03-28 |
2023-10-05 |
Empirico Inc. |
Modified oligonucleotides
|
|
CN119183457A
(zh)
|
2022-04-15 |
2024-12-24 |
达因疗法公司 |
用于治疗强直性肌营养不良的肌肉靶向复合物和制剂
|
|
KR20250042734A
(ko)
|
2022-07-22 |
2025-03-27 |
스미또모 가가꾸 가부시끼가이샤 |
올리고뉴클레오티드의 제조 방법
|
|
WO2024024873A1
(ja)
|
2022-07-28 |
2024-02-01 |
住友化学株式会社 |
チオ化溶液
|
|
EP4561636A1
(en)
|
2022-07-29 |
2025-06-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
EP4581143A1
(en)
|
2022-08-29 |
2025-07-09 |
University of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
KR20250075637A
(ko)
|
2022-09-23 |
2025-05-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Mecp2 발현을 감소시키기 위한 화합물 및 방법(compounds and methods for reducing mecp2 expression)
|
|
EP4593903A1
(en)
*
|
2022-09-29 |
2025-08-06 |
Celanese EVA Performance Polymers LLC |
Implantable medical device for the delivery of a nucleic acid
|
|
WO2024071099A1
(ja)
|
2022-09-29 |
2024-04-04 |
国立大学法人東京医科歯科大学 |
５'－シクロプロピレン修飾を含む核酸分子
|
|
JPWO2024089953A1
(enExample)
|
2022-10-27 |
2024-05-02 |
|
|
|
AU2023371614A1
(en)
|
2022-11-04 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
CN120500498A
(zh)
|
2022-11-14 |
2025-08-15 |
瑞泽恩制药公司 |
用于成纤维细胞生长因子受体3介导的至星形胶质细胞的递送的组合物及方法
|
|
KR20250128304A
(ko)
|
2022-12-26 |
2025-08-27 |
스미또모 가가꾸 가부시끼가이샤 |
올리고뉴클레오티드의 제조 방법
|
|
WO2024153586A1
(en)
|
2023-01-16 |
2024-07-25 |
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
WO2024192115A1
(en)
*
|
2023-03-14 |
2024-09-19 |
Thomas Jefferson University |
Compositions and methods for the treatment of cancer
|